FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/08/2023
Voltar para busca
Dado oficial do USPTO
APEXP
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
30
Atualização mais recente
07/08/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
9, 42
Data de depósito
27/09/2021
Data de registro
28/03/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
28/03/2023
Última transação
28/03/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
16
Localização do titular
ES
Examinador
MESSICK, TABITHA LEE
Unidade examinadora
L40
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
T. S. (pessoa física)
Representantes
John G. Tutunjian Tutunjian & Bitetto, P.C.
Classificação técnica
Classes Nice
Classe 9Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 9
Downloadable software for the research and development of pharmaceutical compositionspharmaceutical productsdiagnostic reagentsantibioticsbiomarkersenzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; downloadable computer software platforms for the research and development of pharmaceutical compositionspharmaceutical productsdiagnostic reagentsantibioticsbiomarkersenzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; downloadable computer software using artificial intelligence for the research and development of pharmaceutical compositionspharmaceutical productsdiagnostic reagentsantibioticsbiomarkersenzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; downloadable computer software platforms using artificial intelligence for the research and development of pharmaceutical compositionspharmaceutical productsdiagnostic reagentsantibioticsbiomarkersenzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria
Classe 42
Software as a service (SaaS) services featuring software for the research and development of pharmaceutical compositionspharmaceutical productsdiagnostic reagentsantibioticsbiomarkersenzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; software as a service (SaaS) services featuring artificial intelligence software for the research and development of pharmaceutical compositionspharmaceutical productsdiagnostic reagentsantibioticsbiomarkersenzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; platform as a service (PaaS) services featuring software platforms for the research and development of pharmaceutical compositionspharmaceutical productsdiagnostic reagentsantibioticsbiomarkersenzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; platform as a service (PaaS) services featuring software platforms using artificial intelligence for the research and development of pharmaceutical compositionspharmaceutical productsdiagnostic reagentsantibioticsbiomarkersenzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; biomedical research services; scientific research for medical purposes in the field of infectious diseases and diseases caused by bacteria; research and development of pharmaceutical compositionspharmaceutical productsdiagnostic reagentsantibioticsbiomarkersenzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; conducting clinical trials for others of pharmaceutical compositionspharmaceutical productsdiagnostic reagentsantibioticsbiomarkersenzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria
Publicações
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
18/07/2023
FIMP
FINAL DISPOSITION PROCESSED
18/07/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
28/06/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
28/03/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
28/03/2023
GPNX
NOTIFICATION PROCESSED BY IB
24/01/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/01/2023
PUBO
PUBLISHED FOR OPPOSITION
10/01/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/01/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/01/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
21/12/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/12/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
17/11/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/11/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
16/11/2022
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
19/10/2022
ATRV
ATTORNEY REVIEW COMPLETED
06/10/2022
LIME
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
06/10/2022
RFNT
REFUSAL PROCESSED BY IB
23/08/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
29/07/2022
RFRR
REFUSAL PROCESSED BY MPU
29/07/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/07/2022
CNRT
NON-FINAL ACTION WRITTEN
02/07/2022
DOCK
ASSIGNED TO EXAMINER
28/06/2022
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
20/06/2022
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
29/05/2022
MAFR
APPLICATION FILING RECEIPT MAILED
23/11/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
19/11/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
18/11/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace APEXP ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.